« Return to News | Awards & Advancement

PharmaNet names Dr. Joel Posener executive medical director, neuroscience

Wednesday, June 29, 2011 12:47 PM

PharmaNet Development Group, a provider of clinical development services, has named Joel Posener, M.D., Executive Medical Director, Neuroscience.

Dr. Posener will support PharmaNet project teams conducting clinical trials in psychiatry and neurology and provide drug development advice to clients in neuroscience.

Previously, Dr. Posener held roles at Wyeth as senior director, neuroscience medical research and senior director, early development and clinical pharmacology. He directed phase II projects in psychiatric indications including cognitive impairment in schizophrenia, bipolar disorder and depression. Dr. Posener has also managed early clinical development programs in schizophrenia, depression and Alzheimer's disease.

Before joining the pharmaceutical industry, Dr. Posener served on the faculty of Harvard Medical School and Washington University School of Medicine in St. Louis, where he was also medical director of Metropolitan St. Louis Psychiatric Center. Dr. Posener currently holds an appointment as Clinical Associate Professor of Psychiatry at Temple University School of Medicine.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.